MedAssets first quarter net revenue increases 39.8% to $130.6 million

MedAssets, Inc. (NASDAQ: MDAS) today announced results for its first quarter ended March 31, 2011, as summarized below:

Net Revenue

First Quarter

Total net revenue for the first quarter of 2011 increased 39.8% to $130.6 million from $93.4 million in the first quarter of 2010, due primarily to the acquisition of The Broadlane Group (Broadlane) in the fourth quarter of 2010.

Comparing period-over-period organic growth, non-GAAP acquisition-affected total net revenue of $136.1 million in the first quarter of 2011 increased 0.2% from non-GAAP acquisition-affected total net revenue of $135.9 million in the first quarter of 2010. Total non-GAAP net revenue in the SCM segment grew 1.1% to $84.9 million from $84.0 million in the first quarter of 2010 as solid growth in group purchasing-related administrative fees were offset by lower decision support services revenue and flat growth in other services and clinical consulting fees. Total non-GAAP net revenue from the RCM segment declined 1.3%, as expected, to $51.2 million from $51.9 million in the first quarter of 2010 due to lower services-related revenue, offset by an increase in technology solutions revenue.

Non-GAAP Adjusted EBITDA

First Quarter

In the first quarter of 2011, total non-GAAP adjusted EBITDA was $40.9 million, or 31.4% of total net revenue, a 47.2% increase over total non-GAAP adjusted EBITDA of $27.8 million, or 29.8% of total net revenue, in the first quarter of 2010.

Comparing period-over-period organic growth, total acquisition-affected non-GAAP adjusted EBITDA in the first quarter of 2011 was $40.9 million, or 30.1% of non-GAAP acquisition-affected total net revenue, an increase of 6.3% from acquisition-affected non-GAAP adjusted EBITDA of $38.5 million, or 28.3% of non-GAAP acquisition-affected total net revenue, in the first quarter of 2010.

Net (Loss) Income and Per Share

First Quarter

Net loss in the first quarter of 2011 was $16.2 million, or a loss of $0.28 per diluted share, versus net income of $5.5 million, or earnings of $0.09 per diluted share, in the first quarter of 2010. The net loss in the first quarter of 2011 was primarily due to acquisition and integration-related costs as well as increased amortization and interest expense related to the purchase of Broadlane.

Non-GAAP cash EPS, defined as EPS excluding non-cash acquisition-related intangible amortization, share-based compensation, acquisition-related expenses and other non-recurring items on a tax-adjusted basis, was $0.17 per diluted share in the first quarter of 2011, versus non-GAAP cash EPS of $0.19 per diluted share in the first quarter of 2010.

Cash Flow and Capital Resources

Net cash provided by operating activities in the first quarter of 2011 increased 5.5% to $18.0 million from $17.1 million in the first quarter of 2010. The company's balance sheet at March 31, 2011 included $901.0 million in total bank and bond debt, net of cash and cash equivalents, which represented leverage of approximately 5.3 times trailing 12-month non-GAAP acquisition-affected adjusted EBITDA.

Reconfirmed 2011 Financial Guidance

Management reiterated its full-year 2011 financial guidance, as follows:

Contracted Revenue Estimates

At March 31, 2011, the Company's rolling 12-month non-GAAP contracted revenue was an estimated $555.4 million ($212.6 million from the RCM segment and $342.8 million from the SCM segment). This is a sequential increase of 1.9% from the first quarter of 2010, and a year-over-year increase of 8.4% excluding contracted revenue added through the Broadlane acquisition.

Source:

MedAssets, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.